Medivolve Inc
Medivolve Inc. is a principal investment firm. It prefers to invest in healthcare technology, industrials, information technology. Medivolve Inc., formerly known as QuestCap Inc, was founded in 2005 and is based in Toronto, Canada.
Medivolve Inc (MEDVF) - Net Assets
Latest net assets as of March 2024: $-17.18 Million USD
Based on the latest financial reports, Medivolve Inc (MEDVF) has net assets worth $-17.18 Million USD as of March 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.76 Million) and total liabilities ($18.94 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-17.18 Million |
| % of Total Assets | -974.35% |
| Annual Growth Rate | N/A |
| 5-Year Change | -904.9% |
| 10-Year Change | -2640.85% |
| Growth Volatility | 1302.98 |
Medivolve Inc - Net Assets Trend (2006–2023)
This chart illustrates how Medivolve Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Medivolve Inc (2006–2023)
The table below shows the annual net assets of Medivolve Inc from 2006 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | $-15.97 Million | -4995.77% |
| 2022-12-31 | $326.26K | -98.17% |
| 2021-12-31 | $17.81 Million | +277.84% |
| 2020-12-31 | $-10.01 Million | -604.62% |
| 2019-12-31 | $1.98 Million | -56.35% |
| 2018-12-31 | $4.55 Million | -13.53% |
| 2017-12-31 | $5.26 Million | +151.61% |
| 2016-12-31 | $2.09 Million | +515.33% |
| 2015-12-31 | $-503.08K | -180.03% |
| 2014-12-31 | $628.65K | -84.63% |
| 2013-12-31 | $4.09 Million | -58.95% |
| 2012-12-31 | $9.96 Million | -23.49% |
| 2011-12-31 | $13.02 Million | +89.91% |
| 2010-12-31 | $6.86 Million | -15.51% |
| 2009-12-31 | $8.12 Million | +301.54% |
| 2008-12-31 | $2.02 Million | +418.62% |
| 2007-12-31 | $389.76K | +1953.88% |
| 2006-12-31 | $-21.02K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Medivolve Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 9253385900.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $67.29 Million | % |
| Other Comprehensive Income | $1.38 Million | % |
| Other Components | $8.24 Million | % |
| Total Equity | $-15.76 Million | 100.00% |
Medivolve Inc Competitors by Market Cap
The table below lists competitors of Medivolve Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Nuheara Limited
PINK:NUHRF
|
$54.11K |
|
TORAY IND INC
BE:TOR1
|
$54.12K |
|
Foresight Group Holdings Limited
LSE:FSG
|
$54.13K |
|
POET TECHNOLOGIES - Dusseldorf Stock Exchang
DU:RI4
|
$54.15K |
|
COMTEX News Network Inc
PINK:CMTX
|
$53.99K |
|
Plasmapp Co. Ltd.
KO:405000
|
$53.97K |
|
Xunlei Ltd
STU:4XN
|
$53.91K |
|
MYRIAD GENETICS
BE:MYD
|
$53.84K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Medivolve Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from 326,262 to -15,763,519, a change of -16,089,781 (-4931.6%).
- Net loss of 16,458,000 reduced equity.
- Other comprehensive income increased equity by 216,983.
- Other factors increased equity by 151,236.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-16.46 Million | -104.41% |
| Other Comprehensive Income | $216.98K | +1.38% |
| Other Changes | $151.24K | +0.96% |
| Total Change | $- | -4931.55% |
Book Value vs Market Value Analysis
This analysis compares Medivolve Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2006-12-31 | $-0.26 | $0.01 | x |
| 2007-12-31 | $5.31 | $0.01 | x |
| 2008-12-31 | $20.77 | $0.01 | x |
| 2009-12-31 | $41.16 | $0.01 | x |
| 2010-12-31 | $24.68 | $0.01 | x |
| 2011-12-31 | $34.50 | $0.01 | x |
| 2012-12-31 | $22.58 | $0.01 | x |
| 2013-12-31 | $9.22 | $0.01 | x |
| 2014-12-31 | $1.40 | $0.01 | x |
| 2015-12-31 | $-1.10 | $0.01 | x |
| 2016-12-31 | $1.62 | $0.01 | x |
| 2017-12-31 | $2.31 | $0.01 | x |
| 2018-12-31 | $1.99 | $0.01 | x |
| 2019-12-31 | $0.87 | $0.01 | x |
| 2020-12-31 | $-1.50 | $0.01 | x |
| 2021-12-31 | $0.64 | $0.01 | x |
| 2022-12-31 | $0.01 | $0.01 | x |
| 2023-12-31 | $-0.58 | $0.01 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Medivolve Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -2397.55%
- • Asset Turnover: 0.29x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-358.94%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2006 | 0.00% | 0.00% | 0.00x | 0.00x | $-132.45K |
| 2007 | -35.76% | -2257.20% | 0.02x | 1.01x | $-178.36K |
| 2008 | -62.64% | 0.00% | 0.00x | 1.04x | $-1.47 Million |
| 2009 | -22.25% | 0.00% | 0.00x | 1.02x | $-2.62 Million |
| 2010 | -29.81% | 0.00% | 0.00x | 1.03x | $-2.73 Million |
| 2011 | -14.13% | 0.00% | 0.00x | 1.02x | $-3.14 Million |
| 2012 | -33.12% | 0.00% | 0.00x | 1.08x | $-4.30 Million |
| 2013 | -144.02% | 0.00% | 0.00x | 1.09x | $-6.30 Million |
| 2014 | -324.35% | 0.00% | 0.00x | 2.06x | $-2.10 Million |
| 2015 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.08 Million |
| 2016 | -36.42% | 0.00% | 0.00x | 1.06x | $-969.95K |
| 2017 | 60.26% | 0.00% | 0.00x | 1.01x | $2.64 Million |
| 2018 | -15.65% | -4033.11% | 0.00x | 1.01x | $-1.17 Million |
| 2019 | -136.98% | 0.00% | -0.07x | 1.16x | $-2.92 Million |
| 2020 | 0.00% | -356.97% | 0.55x | 0.00x | $-36.78 Million |
| 2021 | -37.12% | -7.61% | 1.46x | 3.33x | $-8.39 Million |
| 2022 | -5628.91% | -1323.13% | 0.07x | 57.68x | $-18.40 Million |
| 2023 | 0.00% | -2397.55% | 0.29x | 0.00x | $-14.88 Million |
Industry Comparison
This section compares Medivolve Inc's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $914,015,556
- Average return on equity (ROE) among peers: -22.24%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Medivolve Inc (MEDVF) | $-17.18 Million | 0.00% | N/A | $54.04K |
| Agilent Technologies Inc (A) | $4.08 Billion | 3.46% | 0.65x | $31.80 Billion |
| Amer Bio Medica (ABMC) | $3.38 Million | -26.64% | 1.08x | $3.55K |
| ADCNF (ADCNF) | $1.77 Billion | 2.65% | 1.64x | $172.01 Million |
| Advanced Biomed Inc. Common Stock (ADVB) | $3.48 Billion | 0.00% | 0.87x | $1.68 Million |
| ANGLE plc (ANPCF) | $18.44 Million | -77.14% | 0.38x | $34.42 Million |
| SeqLL Inc. (ATLN) | $8.18 Million | -45.26% | 0.31x | $35.63K |
| Avricore Health Inc (AVCRF) | $2.20 Million | -79.50% | 0.04x | $3.22 Million |
| Aspira Womens Health Inc (AWH) | $-11.46 Million | 0.00% | 0.00x | $664.47K |
| Biodesix Inc (BDSX) | $-198.03 Million | 0.00% | 0.00x | $50.38 Million |
| bioAffinity Technologies, Inc. (BIAF) | $-15.79 Million | 0.00% | 0.00x | $5.08 Million |